Carregant...
Current development of the second generation of mTOR inhibitors as anticancer agents
The mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, acts as a “master switch” for cellular anabolic and catabolic processes, regulating the rate of cell growth and proliferation. Dysregulation of the mTOR signaling pathway occurs frequently in a variety of human tumors, and...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Sun Yat-sen University Cancer Center
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3249493/ https://ncbi.nlm.nih.gov/pubmed/22059905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5732/cjc.011.10281 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|